Home Draft_NewImage

Committed to improving the lives of patients with inflammatory diseases through innovative T-cell research

Atopic Dermatitis

CBP-201, an anti-IL-4Ra antibody, is in clinical trial development to treat atopic dermatitis (AD) patients with moderate-to-severe AD. A Phase 2b study in this population showed CBP-201 met the primary endpoint of eczema area and severity index (EASI) percent reduction from baseline at Week 16 and were statistically superior to placebo. Clinical trials are ongoing for CBP-201 in patients with moderate-to-severe atopic dermatitis (AD) and moderate-to-severe persistent asthma with type 2 inflammation.


CBP-307, a small molecule modulator of S1P1, is currently being evaluated in a global Phase 2 clinical study in patients with ulcerative colitis. CBP-307 is not a pro-drug and does not require conversion to an active form in the human body following administration.


We are developing CBP-174, a peripherally acting, small molecule H3R antagonist, for oral administration to treat chronic pruritus associated with skin inflammation. CBP-174 is currently being evaluated in a Phase 1 dose-escalation study in healthy subjects. Our preclinical models have indicated that CBP-174 led to reductions in scratching in mice within the first 30 minutes of dosing, which could potentially translate to rapid reduction in pruritus in the clinic.

Connect Biopharma is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research.  

With operations and expertise in China, the United States and Australia and clinical development activities in those geographies as well as Europe, Connect Biopharma is building a rich pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology. Our core expertise is in the use of functional cellular assays with T cells to screen and discover potent drug candidates against immune targets. Our two most advanced clinical-stage programs include highly differentiated product candidates against validated targets.

Many autoimmune and allergic inflammatory diseases share a common biologic origin: inappropriate activity of Th2 cells that normally play a critical role in preventing infections and cancer. Abnormal Th2 activity leads to inflammation and destruction of healthy tissue. Our expertise in Th2 biology, and our proprietary Immune Modulation Technology Platform allow us to radically reduce the time and cost of discovering novel small molecules and biologics that have best- and first-in-class potential as therapies for serious autoimmune and inflammatory diseases that have significant unmet need.